{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"description":"Maximum tolerated dose (MTD) defined as dose most closely associated with a 20% probability of experiencing a toxicity \\<= 1 year from start of SBRT from following dose-limiting toxicities: Gr 3-5 Cardiac: Pericardial effusion, Pericarditis, Restrictive cardiomyopathy; Gr 4-5 GI: Dysphagia, Esophagitis, Esophageal fistula/obstruction/perforation/stenosis/ulcer/hemorrhage; Gr 3-5 Nervous System Disorders: Brachial plexopathy, Recurrent laryngeal nerve palsy, Myelitis; Gr 3-5 Respiratory: Atelectasis (gr 4-5 only), Bronchopulmonary/mediastinal/pleural/tracheal hemorrhage, Bronchial/pulmonary/bronchopleural/tracheal fistula, Hypoxia (provided gr 3 is worse than baseline), Bronchial/tracheal obstruction, Pleural effusion, Pneumonitis, Pulmonary fibrosis; Changes in Pulmonary Function Tests per SBRT Pulmonary Toxicity Scale, Gr 3-5: FEV1 decline, FVC decline; Any Gr 5 adverse event attributed to treatment. Dose level was determined by time-to-event continual reassessment method (TITE-CRM).","groups":[{"id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From start of SBRT to 1 year","title":"(Phase I) Maximum Tolerated Dose of Stereotactic Body Radiotherapy (SBRT) as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0","type":"PRIMARY","unitOfMeasure":"Gy/FX"}